Series B11 February 2022

Nuclera secures £31.4m Series B financing led by M&G to scale benchtop bioprinting

The Cambridge biotechnology company has raised £31.4m from investors including M&G and Amadeus Capital Partners to advance its desktop protein printer.

£31.4MSeries B

Nuclera builds benchtop protein systems designed to accelerate expression and purification workflows in research laboratories. The biotechnology enterprise operates out of bases in Cambridge and Boston.

Biotech firm Nuclera has secured £31.4m in the first close of its Series B financing round. The investment was backed by a syndicate of new and existing institutional partners, led by M&G alongside Amadeus Capital Partners, E Ink, RT Partners, Future Planet Capital, British Business Bank Future Fund, and G. K. Goh.

The proceeds from the raise will be directed towards accelerating the commercialisation and development of the company's eProtein desktop bioprinter. The funding will also support the expansion of the platform towards an all-encompassing proteomics instrument designed to unify protein expression and characterisation.

From the founder

"There’s a fundamental productivity problem in biotech today. A biotech scientist needs to know how to make proteins to design drugs. That’s like expecting a computer scientist to know how to build a computer to design software,"

Michael Chen

CEO at Nuclera

Investor perspective

"Nuclera’s eProtein platform unites the very fragmented workflow that currently exists in proteomics. Nuclera is bringing rapid prototyping—a concept that did not exist until now—to biotech, and by speeding up research and opening up completely new avenues of innovation, it will have a far-reaching impact in numerous markets. We have been very impressed with the quality of the team that Michael and his co-founders have assembled and the unique technology they are developing."

Andrea Traversone

Managing Partner, Amadeus Capital Partners